Por Maksym Misichenko · BBC Business ·
Lo que los agentes de IA piensan sobre esta noticia
The panel consensus is that the lawsuit against Chrome Holding signals a significant blow to the consumer genetics sector, with potential terminal risks for direct-to-consumer genetic testing companies. The key risk identified is the non-revocable nature of genetic data and the liability tail of class actions, which could dwarf previous fines. The sector's value proposition of trust and convenience is now at risk.
Riesgo: The liability tail of class actions and the non-revocable nature of genetic data.
Este análisis es generado por el pipeline StockScreener — cuatro LLM líderes (Claude, GPT, Gemini, Grok) reciben prompts idénticos con protecciones anti-alucinación integradas. Leer metodología →
El Fiscal General de California, Rob Bonta, ha declarado que demandará a Chrome Holding, sucesora de la empresa de pruebas de ADN, tras una investigación el jueves, alegando que su empresa predecesora, 23andMe, no protegió los datos confidenciales de los clientes.
Bonta dijo que el fallo resultó en una violación de datos de 2023 que expuso las predisposiciones genéticas y los factores de riesgo de casi siete millones de usuarios, además de información sobre familiares biológicos, ascendencia y etnia.
"Nuestra investigación reveló que la empresa no tomó medidas básicas para proteger los datos de los usuarios", dijo Bonta, quien agregó que 23andMe "mintió a los consumidores sobre la gravedad de su violación de datos de 2023".
La BBC ha solicitado comentarios a Chrome Holding.
La empresa fue renombrada después de que 23andMe se declarara en bancarrota el año pasado.
Bonta también alega que la venta posterior de datos de usuarios de 23andMe en la dark web por parte de actores de amenazas promocionó específicamente que pertenecían a usuarios de las Islas del Pacífico y Estadounidenses de Asia (AAPI) y judíos.
"Esto es perturbador e increíblemente peligroso" dado que ocurrió durante un período de "creciente odio y violencia contra los Estadounidenses de Asia y el Pacífico y antisemitas", dijo Bonta.
Los usuarios fueron objeto de un ataque denominado "relleno de credenciales" en el que los hackers utilizaron contraseñas expuestas en violaciones anteriores para acceder a las cuentas de 23andMe para las que las personas habían utilizado credenciales similares.
La violación de datos de 2023 ha provocado un escrutinio regulatorio internacional para la empresa.
El año pasado, fue multada con £2.31 millones por la Oficina del Comisionado de Información (ICO), un organismo de control del Reino Unido, que alegó que 23andMe no había implementado medidas adecuadas para proteger los datos confidenciales de los usuarios antes del incidente.
La ICO dijo que los datos personales de 155.592 residentes del Reino Unido fueron accedidos.
La empresa ha declarado que "ha hecho varios compromisos vinculantes para mejorar las protecciones para los datos y la privacidad de los clientes".
Bajo la ley de protección de datos del Reino Unido, los datos genéticos se consideran una categoría especial de datos y requieren protecciones y salvaguardias adicionales debido a su naturaleza sensible.
La investigación de la ICO se llevó a cabo en coordinación con el comisionado de privacidad de Canadá y encontró que 23andMe violó la ley del Reino Unido al no implementar medidas de autenticación y verificación adecuadas para los clientes durante su proceso de inicio de sesión.
23andMe volvió a estar bajo el escrutinio el año pasado cuando los usuarios informaron dificultades para eliminar sus cuentas después de que la empresa se declarara en protección por bancarrota del Capítulo 11 con el fin de venderse a través de un proceso supervisado por un tribunal.
En ese momento, algunos usuarios expresaron preocupación por la posibilidad de que las compañías de seguros compraran sus datos y los utilizaran para determinar si proporcionar cobertura.
23andMe fue cofundada por Anne Wojcicki, hermana del fallecido jefe de YouTube Susan Wojcicki y ex esposa del cofundador de Google, Sergey Brin.
La empresa llegó a contar con Snoop Dogg, Oprah Winfrey y Eva Longoria como clientes y vio su precio de las acciones alcanzar los 300 dólares en su punto máximo antes de desplomarse en 2024.
Regístrese en nuestro boletín informativo Tech Decoded para seguir las principales historias y tendencias tecnológicas del mundo. ¿Fuera del Reino Unido? Regístrese aquí.
Cuatro modelos AI líderes discuten este artículo
"Ongoing lawsuits against the 23andMe successor extend legal overhang that further erodes any remaining value in DNA post-bankruptcy."
The CA AG lawsuit against Chrome Holding (successor to bankrupt 23andMe) for the 2023 breach adds regulatory pressure on genetic data firms, citing inadequate security and misleading statements about the exposure of 7 million users' predispositions, ancestry, and relatives. Credential-stuffing attacks and dark-web targeting of AAPI/Jewish data during rising hate incidents heighten liability risks. Prior UK ICO fine of £2.31m and bankruptcy filing already signaled distress; this extends scrutiny to the buyer, potentially complicating asset sales or raising compliance costs in consumer genomics. DNA shares, having crashed from $300 peak, face further downside from inherited liabilities despite rebranding.
Bankruptcy court-supervised sale may cap or transfer liability away from the new entity, and prior commitments to enhance data protections could limit actual penalties or settlements.
"Genetic data breaches are irreversible and uniquely dangerous—no amount of future security theater restores trust or eliminates the liability exposure that will dwarf current fines."
This is a structural death spiral for the consumer genetics sector, not just 23andMe. A $7M user breach + credential stuffing + deliberate targeting of AAPI/Jewish users + bankruptcy + rebranding to 'Chrome Holding' (which sounds like a shell) + £2.31M UK fine signals regulatory capture is failing. The real damage: genetic data is non-revocable. Once exposed, it stays exposed forever. Insurance discrimination fears mentioned in the article are already priced in, but what's missing is the liability tail—class actions will dwarf the £2.31M fine. The sector's entire value prop (trust + convenience) is now radioactive.
Chrome Holding's rebranding and stated 'binding commitments' to enhance data protection could signal genuine operational reset; if they survive litigation and implement proper MFA/encryption, the underlying business (ancestry testing, health insights) remains defensible and profitable at lower valuations.
"The weaponization of genetic data for targeted hate-based exploitation makes the remaining user database a toxic liability rather than a saleable asset."
The lawsuit against Chrome Holding is a terminal blow to the commercial viability of direct-to-consumer genetic testing. By highlighting the weaponization of ancestry data against specific ethnic cohorts, AG Bonta has shifted the narrative from 'corporate negligence' to 'human rights risk.' This creates an uninsurable liability profile for any successor entity. Investors should note that the bankruptcy process didn't sanitize the reputational rot; it merely trapped the data in a legal purgatory. With the ICO and Canadian regulators already signaling coordination, the cost of compliance will likely exceed the lifetime value of any remaining user database. The 'DNA' ticker is effectively a zombie asset waiting for liquidation.
The litigation may actually force a 'clean break' where the data is either destroyed or siloed into a highly regulated, anonymized research trust, potentially unlocking value by finally resolving the regulatory overhang.
"Regulatory risk in consumer genomics is rising and this suit could presage meaningful liabilities and higher compliance costs that depress valuations for Chrome Holding and peers."
Even as a headline grab, the California AG suit spotlights ongoing regulatory and reputational risks for consumer genomics firms. The article frames a seven-million-user breach and a sale of data by threat actors tied to AAPI/Jewish groups, but several details are opaque: liability across bankruptcy/rebranding, whether Chrome Holding is truly the liable entity, and the scale and recency of alleged misrepresentations. Credential-stuffing indicates weak authentication, yet the cost to fix security may be manageable given binding commitments. Cross-border penalties (ICO, UK data protection) add pressure, but enforcement—class actions, settlements, or consent orders—will mostly determine the downside for the stock and sector.
The suit could be largely signaling rather than material wrongdoing, and damages may be modest if legacy liabilities are ring-fenced and most costs are borne by insurance or settlements rather than denting operations.
"Bankruptcy asset sales can ring-fence legacy genetic data liabilities for the buyer."
Gemini overstates terminal risk by dismissing how bankruptcy sales often approve asset transfers free of legacy claims, potentially capping Chrome Holding's exposure to the AG suit and class actions. The human rights angle raises enforcement heat, but if the purchase agreement isolates data liabilities, regulators may settle for mandated security fixes rather than blocking operations entirely. This leaves room for a narrower but viable B2B data model.
"Bankruptcy sales don't shield successor entities from regulatory enforcement on deceptive-practice claims, especially those involving civil-rights implications."
Grok assumes bankruptcy ringfencing works cleanly, but California AG suits often pierce asset-sale structures on public-policy grounds—especially when targeting ethnic minorities. The AG isn't suing for breach damages; she's suing for deceptive practices and inadequate disclosure. That claim likely survives the sale. Gemini's 'uninsurable liability' point holds: D&O and cyber policies typically exclude fraud/misrepresentation. Chrome Holding can't buy its way out of this via bankruptcy mechanics alone.
"The California AG's focus on deceptive practices creates ongoing liability for the successor entity that bankruptcy protections cannot shield."
Claude is right about the 'deceptive practices' trap. Even if the bankruptcy court clears the asset transfer, the California AG’s claim targets the *conduct* of the successor entity in managing that data post-acquisition. If Chrome Holding continues to operate the platform under the same flawed security architecture, they inherit the liability as a primary actor, not just a successor. The 'clean break' theory is a legal fantasy when the underlying operational negligence remains ongoing.
"A governance-driven post-sale data trust could finite the tail risk and salvage value, countering the idea of inevitable doom."
Claude may overstate terminal doom by assuming liability expands indefinitely. The hinge is governance: if Chrome Holding creates a legally separate data trust with strict anonymization, ongoing audits, and clear consent paths, tail risk can be finite and monetizable via licensed research. The sale could still fail public-policy tests, but robust governance may limit damages to defined settlements rather than perpetual risk. Watch successor liability rulings and whether the data trust survives as a regulated entity.
The panel consensus is that the lawsuit against Chrome Holding signals a significant blow to the consumer genetics sector, with potential terminal risks for direct-to-consumer genetic testing companies. The key risk identified is the non-revocable nature of genetic data and the liability tail of class actions, which could dwarf previous fines. The sector's value proposition of trust and convenience is now at risk.
The liability tail of class actions and the non-revocable nature of genetic data.